Our Technology

DOTBODY TECHNOLOGY

DotBio's domain therapeutic antibody ("DotBody") technology platform is based on a human-derived domain antibody template from which it generates new DotBody modules.   

The DotBody modules are optimized for modularity i.e., their ability to be used as building blocks to assemble more complex antibody structures. Each DotBody module is also optimized for target specificity, high potency, high expression, solubility, stability and scalability.  

The DotBody technology has been validated in the pre-clinical studies, displaying positive results. 

DotBio’s key differentiation is the ability to produce many antibody prototypes in parallel, thereby speeding up the process of candidate molecule identification. This is made possible as DotBio generates different antibody prototypes by simply connecting the Dots.  

The DotBody technology is compatible with many antibody formats. These include:  

• Small antibodies without Fc region which are ideal for higher tissue penetration 

• Bi- and tri-specific antibodies generated by adding DotBody modules to monoclonal antibodies through protein fusion  

• Bi- and tri-specific antibodies generated by knob-into-hole technology 

• High valency molecules 

• Bi- and tri-specific ADCs through compatibility with ADC technologies